Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2014

View Archived Issues

Oncodesign presents novel HER2-targeting DARPins

Proxalutamide, a novel androgen receptor antagonist for CRPC and prostate cancer

Novel selective inhibitors of EGFR containing drug resistant mutation T790M

Pfizer discloses new Trk-A inhibitors

Boehringer Ingelheim to evaluate BI-144807 in patients with newly diagnosed wet AMD

Mitochondrial genes delivered in vivo confer protection against renal I/R injury

Researchers use B-cell ELISPOT assay to measure DP6-001-induced gp120-specific B cell responses

Eli Lilly to begin a phase II study of LY-2944876 in type 2 diabetes

Synergy Pharmaceuticals reports data from phase IIb study of plecanatide in IBS-C

GSK is to begin a phase I first-in-human trial of GSK-2798745

Researchers from the University of Utah divulge novel BTK inhibitors

Achillion advances ACH-3422 into phase I; begins phase II pilot study of ACH-3102

Novel PTGDR2 antagonists disclosed by Merck & Co.

Trevena begins phase II study of TRV-130 in acute postoperative pain

Bristol-Myers Squibb presents novel IAP agonists for cancer

Janssen Biotech to begin phase III study of daratumumab in multiple myeloma

Novel approach for QBECO SSI therapy in Crohn's disease patients

GlaxoSmithKline obtains FDA priority review designation for Promacta/Revolade

Fibrotech acquired by Shire

Complexa initiates phase I trial of kidney injury candidate

Isis discloses data from phase II trial in patients with hypertriglyceridemia and type 2 diabetes

Merrimack's nanoparticle irinotecan increases survival in pancreatic cancer study

SAGE Therapeutics' status epilepticus drug receives U.S. orphan drug designation

ADXS-HPV receives FDA orphan drug designation for invasive cervical cancer

FDA clears IND for P-321 ophthalmic solution

FDA grants orphan drug designation to OncoMed's demcizumab for pancreatic cancer

Theravance discloses positive results from phase II fibromyalgia trial

Teva Pharmaceutical reports data from pivotal phase III study of hydrocodone bitartrate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...